FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings
Corcept’s relacorilant was rejected for hypercortisolism late last year—a decision which CEO Joseph Belanoff expressed surprise with at the time.
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings Read More »
